NO20013669L - Reverse hydroksamatinhibitorer av matriks metalloproteinaser - Google Patents

Reverse hydroksamatinhibitorer av matriks metalloproteinaser

Info

Publication number
NO20013669L
NO20013669L NO20013669A NO20013669A NO20013669L NO 20013669 L NO20013669 L NO 20013669L NO 20013669 A NO20013669 A NO 20013669A NO 20013669 A NO20013669 A NO 20013669A NO 20013669 L NO20013669 L NO 20013669L
Authority
NO
Norway
Prior art keywords
hydroxamine
inhibitors
reverse
matrix metalloproteinases
metalloproteinases
Prior art date
Application number
NO20013669A
Other languages
English (en)
Norwegian (no)
Other versions
NO20013669D0 (no
Inventor
Michael L Curtin
Yujia Dai
Steven K Davidsen
Howard R Heyman
James H Holmes
Michael R Michaelides
Douglas H Steinman
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of NO20013669D0 publication Critical patent/NO20013669D0/no
Publication of NO20013669L publication Critical patent/NO20013669L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/28—Radicals substituted by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20013669A 1999-01-27 2001-07-26 Reverse hydroksamatinhibitorer av matriks metalloproteinaser NO20013669L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23908799A 1999-01-27 1999-01-27
PCT/US2000/002038 WO2000044739A1 (en) 1999-01-27 2000-01-27 Reverse hydroxamate inhibitors of matrix metalloproteinases

Publications (2)

Publication Number Publication Date
NO20013669D0 NO20013669D0 (no) 2001-07-26
NO20013669L true NO20013669L (no) 2001-09-27

Family

ID=22900549

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013669A NO20013669L (no) 1999-01-27 2001-07-26 Reverse hydroksamatinhibitorer av matriks metalloproteinaser

Country Status (28)

Country Link
US (1) US20020007060A1 (de)
EP (1) EP1147101B1 (de)
JP (1) JP4718686B2 (de)
KR (1) KR100748010B1 (de)
CN (1) CN1222519C (de)
AR (1) AR029329A1 (de)
AT (1) ATE228122T1 (de)
AU (1) AU764383B2 (de)
BG (1) BG105782A (de)
BR (1) BR0007278A (de)
CA (1) CA2358951C (de)
CO (1) CO5150194A1 (de)
CZ (1) CZ20012591A3 (de)
DE (1) DE60000819T2 (de)
DK (1) DK1147101T3 (de)
ES (1) ES2187443T3 (de)
HK (1) HK1043115A1 (de)
HU (1) HUP0105477A2 (de)
IL (1) IL143713A0 (de)
NO (1) NO20013669L (de)
NZ (1) NZ512372A (de)
PL (1) PL349771A1 (de)
PT (1) PT1147101E (de)
SK (1) SK10582001A3 (de)
TR (1) TR200102159T2 (de)
TW (1) TWI225486B (de)
WO (1) WO2000044739A1 (de)
ZA (1) ZA200104979B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
WO2003063762A2 (en) * 2001-01-12 2003-08-07 Abbott Laboratories Process for the preparation of matrix metalloproteinase inhibitors
ATE420068T1 (de) 2001-09-07 2009-01-15 Kaken Pharma Co Ltd Reverse hydroxamsäurederivate
EP2298733B1 (de) * 2005-06-27 2016-05-25 Nabriva Therapeutics AG Pleuromutilinderivate mit einer Hydroxyamino- oder Acyloxyaminocycloalkylgruppe
AU2008350907A1 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
WO2015107139A1 (en) 2014-01-17 2015-07-23 Proyecto De Biomedicina Cima, S.L. Compounds for use as antifibrinolytic agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE225343T1 (de) * 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren

Also Published As

Publication number Publication date
IL143713A0 (en) 2002-04-21
CA2358951A1 (en) 2000-08-03
SK10582001A3 (sk) 2001-12-03
CA2358951C (en) 2009-10-20
CN1339032A (zh) 2002-03-06
ES2187443T3 (es) 2003-06-16
TWI225486B (en) 2004-12-21
ZA200104979B (en) 2002-09-18
PT1147101E (pt) 2003-04-30
TR200102159T2 (tr) 2001-12-21
US20020007060A1 (en) 2002-01-17
CZ20012591A3 (cs) 2001-12-12
KR100748010B1 (ko) 2007-08-09
EP1147101B1 (de) 2002-11-20
JP4718686B2 (ja) 2011-07-06
BR0007278A (pt) 2001-11-27
CN1222519C (zh) 2005-10-12
AR029329A1 (es) 2003-06-25
WO2000044739A1 (en) 2000-08-03
HUP0105477A2 (hu) 2002-05-29
PL349771A1 (en) 2002-09-09
AU2739100A (en) 2000-08-18
KR20010101709A (ko) 2001-11-14
NZ512372A (en) 2003-01-31
CO5150194A1 (es) 2002-04-29
BG105782A (en) 2002-04-30
DE60000819D1 (de) 2003-01-02
DE60000819T2 (de) 2003-09-04
NO20013669D0 (no) 2001-07-26
EP1147101A1 (de) 2001-10-24
HK1043115A1 (zh) 2002-09-06
JP2002535398A (ja) 2002-10-22
ATE228122T1 (de) 2002-12-15
DK1147101T3 (da) 2003-03-10
AU764383B2 (en) 2003-08-14

Similar Documents

Publication Publication Date Title
DK0923585T3 (da) Phosphinatbaserede inhibitorer af matrixmetalloproteinaser
ATE237329T1 (de) Metalloprotease inhibitoren
ATE512949T1 (de) Reninhemmer
NO20024528L (no) Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen
MA26812A1 (fr) Pyrimidine-2,4,6-triones inhibitrices de metalloproteinases
NO20016034D0 (no) Inhibitorer av aspartylprotease
ATE363478T1 (de) Renin inhibitoren
NO20014243D0 (no) Dihetero-substituerte metalloprotease inhibitorer
EE200100611A (et) NOS inhibiitorite uued farmatseutilised kombinatsioonid
AU2001265182A1 (en) Inhibitors of matrix metalloproteinases
DK1047665T3 (da) Matrix metalloprotease inhibitorer
DE60024101D1 (de) Enzyminhibitoren
NO20013669D0 (no) Reverse hydroksamatinhibitorer av matriks metalloproteinaser
DE60009260D1 (de) Thiopyranderivate as mmp-inhibitoren
EE200100084A (xx) NOS inhibiitorite uued farmatseutilised kasutusv�imalused
ID30381A (id) Penggunaan arilalkanoilpiridazina
FI19991835A (fi) Tiedon julkaiseminen
SI1147101T1 (en) Reverse hydroxamate inhibitors of matrix metalloproteinases
SE0004239D0 (sv) New use of an inhibitor
UA3299S (uk) Комплект етикеток
UA3442S (uk) Комплект етикеток
UA3165S (uk) Комплект етикеток
UA3351S (uk) Комплект етикеток
UA3167S (uk) Комплект етикеток
UA3176S (uk) Комплект етикеток

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application